NCT01416337View on ClinicalTrials.gov

Absolute Bioavialability of GSK1120212

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 20, 2011

Primary Completion Date

December 17, 2011

Study Completion Date

December 17, 2011

Conditions
Cancer
Interventions
DRUG

GSK1120212

2 mg single dose tablet on Day 1 of study

DRUG

GSK1120212B

A single administration of a slow 1 minute IV push on Day 1.

Trial Locations (1)

98418

GSK Investigational Site, Tacoma

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01416337 - Absolute Bioavialability of GSK1120212 | Biotech Hunter | Biotech Hunter